Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, ra... by Xu, Jianming, Prof, Kato, Ken, MD, Raymond, Eric, Prof, Hubner, Richard A, BM BCh, Shu, Yongqian, Prof, Pan, Yueyin, Prof, Park, Sook Ryun, Prof, Ping, Lu, MD, Jiang, Yi, MD, Zhang, Jingdong, Prof, Wu, Xiaohong, MD, Yao, Yuanhu, MD, Shen, Lin, Prof, Kojima, Takashi, Prof, Gotovkin, Evgeny, MD, Ishihara, Ryu, MD, Wyrwicz, Lucjan, Prof, Van Cutsem, Eric, Prof, Jimenez-Fonseca, Paula, MD, Lin, Chen-Yuan, MD, Wang, Lei, MD, Shi, Jingwen, PhD, Li, Liyun, MD, Yoon, Harry H, Prof

Get full text